Telomir Pharmaceuticals (NASDAQ:TELO) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) released its earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04, Zacks reports.

Telomir Pharmaceuticals Stock Up 2.5%

Shares of Telomir Pharmaceuticals stock opened at $1.46 on Wednesday. Telomir Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $7.08. The firm’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.72. The firm has a market capitalization of $46.97 million, a P/E ratio of -3.83 and a beta of -0.53.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after acquiring an additional 10,880 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $33,000. Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $62,000. Finally, Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $95,000.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.